Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseasesSCHNEIDER, Joachim; PHILIPP, Monika; VELCOVSKY, Hans-Georg et al.Anticancer research. 2003, Vol 23, Num 2A, pp 885-893, issn 0250-7005, 9 p.Conference Paper

Cyfra 21-1 in diagnosis of distant metastases of head and neck carcinomaHOFFMANN-FAZEL, Asita; HOFFMANN, Markus; GOTTSCHLICH, Stefan et al.Anticancer research. 2003, Vol 23, Num 2A, pp 917-920, issn 0250-7005, 4 p.Conference Paper

CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patientsMULEY, Thomas; DIENEMANN, Hendrik; EBERT, Werner et al.Anticancer research. 2004, Vol 24, Num 3B, pp 1953-1956, issn 0250-7005, 4 p.Article

Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLCMULEY, Thomas; DIENEMANN, Hendrik; EBERT, Werner et al.Anticancer research. 2003, Vol 23, Num 5B, pp 4085-4093, issn 0250-7005, 9 p.Article

Cytokeratin- 19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancerUENISHI, T; KUBO, S; HIROHASHI, K et al.British journal of cancer. 2003, Vol 88, Num 12, pp 1894-1899, issn 0007-0920, 6 p.Article

Apport du dosage sérique du Cyfra 21-1 dans le cancer du cavum en Tunisie = Contribution of serum Cyfra 21-1 in nasopharyngeal carcinoma in TunisiaJMAL, Aouatef; BOUSSEN, Hamouda; ABDENNEBI, Monia et al.Bulletin du cancer. 2004, Vol 91, Num 4, pp 369-372, issn 0007-4551, 4 p.Article

Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levelsKASHIWABARA, K; NAKAMURA, H; ESAKI, T et al.Clinica chimica acta. 2000, Vol 294, Num 1-2, pp 105-113, issn 0009-8981Article

Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinomaAYUDE, Daniel; GACIO, Gloria; DE LA CADENA, Maria Paez et al.Oncology reports. 2003, Vol 10, Num 5, pp 1345-1350, issn 1021-335X, 6 p.Article

Analyse critique de la bibliographie sur l'utilisation de paramètres biologiques sanguins pour l'évaluation pronostique du cancer bronchopulmonaire primitif = Bibliographic analysis of the use of laboratory blood parameters for the prognosis of primary lung cancerWATINE, J; ROUZAUD, P; CHARET, J.-C et al.Annales de biologie clinique (Paris). 1999, Vol 57, Num 1, pp 57-68, issn 0003-3898Article

Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinomaYAN FEI DENG; PING CHEN; YONG ZHI LIN et al.Journal of laryngology and otology. 2003, Vol 117, Num 3, pp 190-194, issn 0022-2151, 5 p.Article

Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damageFUJITA, J; OHTSUKI, Y; BANDOH, S et al.Respiratory medicine. 2004, Vol 98, Num 4, pp 294-300, issn 0954-6111, 7 p.Article

Clinical significance of serum CYFRA 21-1 in gastric cancerNAKATA, B; CHUNG, Y. S; KATO, Y et al.British journal of cancer. 1996, Vol 73, Num 12, pp 1529-1532, issn 0007-0920Article

Papillary mesothelioma of the peritoneum in the absence of asbestos exposureMEISTER, T; BIRKFELLNER, T; POREMBA, C et al.Zeitschrift für Gastroenterologie. 2003, Vol 41, Num 4, pp 329-332, issn 0044-2771, 4 p.Article

Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinomaGOUMAS, P; MASTRONIKOLIS, N. S; MASTORAKOU, A. N et al.ORL. 1997, Vol 59, Num 2, pp 106-114, issn 0301-1569Article

Cyfra 21-1 and TPA as markers in malignant mesotheliomaBONFRER, J. M. G; SCHOUWINK, J. H; KORSE, C. M et al.Anticancer research. 1997, Vol 17, Num 4B, pp 2971-2973, issn 0250-7005Conference Paper

CYFRA 21-1 et cancers bronchiques = CYFRA 21-1 and bronchial cancerPUJOL, J.-L; GRENIER, J; MICHEL, F.-B et al.Revue des maladies respiratoires. 1995, Vol 12, Num 6, pp 533-541, issn 0761-8425Article

Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusionsLEE, Y. C; KNOX, B. S; GARRETT, J. E et al.Australian and New Zealand journal of medicine. 1999, Vol 29, Num 6, pp 765-769, issn 0004-8291Article

Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinomaHUANG, M.-S; JONG, S.-B; TSAI, M.-S et al.Respiratory medicine. 1997, Vol 91, Num 3, pp 135-142, issn 0954-6111Article

Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN)NIEMANN, A. M; GOEROEGH, T; GOTTSCHLICH, S et al.Anticancer research. 1997, Vol 17, Num 4B, pp 2859-2860, issn 0250-7005Conference Paper

CYFRA 21-1 as a tumour marker for bronchogenic carcinomaRAPELLINO, M; NIKLINSKI, J; PECCHIO, F et al.The European respiratory journal. 1995, Vol 8, Num 3, pp 407-410, issn 0903-1936Article

CYFRA 21-1PUJOL, J.-L.Revue des maladies respiratoires. Supplément. 1997, Vol 14, Num 3, pp 3S31-3S36, issn 1166-8253Article

Cytokeratins as serum markers in lung cancer : A comparison of CYFRA 21-1 and TPSPUJOL, J.-L; GRENIER, J; PARRAT, E et al.American journal of respiratory and critical care medicine. 1996, Vol 154, Num 3, pp 725-733, issn 1073-449X, 1Article

Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1PRADIER, O; HILLE, A; SCHMIBERGER, H et al.Cancer radiothérapie. 2002, Vol 6, Num 1, pp 15-21, issn 1278-3218Article

CYFRA 21-1 serum analysis in patients with esophageal cancerBROCKMANN, Jens G; NOTTBERG, Hubertus St; GLODNY, Bernhard et al.Clinical cancer research. 2000, Vol 6, Num 11, pp 4249-4252, issn 1078-0432Article

Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancerMIKLINSKI, J; FURMAN, M; CHYCZEWSKA, E et al.The European respiratory journal. 1995, Vol 8, Num 2, pp 291-294, issn 0903-1936Article